Q2 2025 Iovance Biotherapeutics Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Transcript 10-Q8-K

Key Points

Positve

Iovance Biotherapeutics Inc (IOVA) reported a 22% growth in total revenue for the second quarter, reaching $60 million.
The company surpassed treating more than 100 patients in a single quarter for the first time with their antagony therapy for advanced melanoma.
Real-world data showed a nearly 49% response rate among patients treated with amago therapy, with a 61% response rate in earlier treatment settings.
Iovance Biotherapeutics Inc (IOVA) is on track to achieve multiple clinical milestones in the second half of the year, including data updates from trials in non-small cell lung cancer and endometrial cancer.
The strategic restructuring is expected to generate more than $100 million in annual cost savings starting in the fourth quarter of 2025.

Negative

Total operating expenses increased to approximately $117 million, up from $102 million in the prior year period, primarily due to higher headcount and clinical trial costs.
The company announced a workforce reduction of approximately 19% as part of its strategic restructuring.
Iovance Biotherapeutics Inc (IOVA) withdrew its submission from the European Medicines Agency due to lack of alignment on clinical data, impacting its European market strategy.
Gross margin was reported at 31%, with expectations for improvement through restructuring and manufacturing optimization.
The company faces challenges in expanding its market presence internationally, with Canadian approval expected imminently but delays in the European Union.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IOVA.OQ - Iovance Biotherapeutics Inc
Q2 2025 Iovance Biotherapeutics Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the IOance Biotherapeutics 2nd quarter 2025 Financial Results conference call. At the time all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session.

To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised.

To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Sarah Pellegrino, senior Vice President, Investor Relations and corporate communications. Please go ahead.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.